https://www.taxtmi.com/news?id=56892 The launch of Perzea, an affordable Pertuzumab biosimilar by Hetero Healthcare with Enzene Biosciences, is described as expanding access to HER2 positive breast cancer treatment by lowering cost barriers. The partnership and Enzene's EnzeneXTM manufacturing technology are presented as the enabling mechanisms for increased domestic biologics production and affordability, framed within national objectives of equitable healthcare access. en-us Thu, 25 Sep 2025 14:46:02 +0530 Thu, 25 Sep 2025 14:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=56892 The launch of Perzea, an affordable Pertuzumab biosimilar by Hetero Healthcare with Enzene Biosciences, is described as expanding access to HER2 positive breast cancer treatment by lowering cost barriers. The partnership and Enzene's EnzeneXTM manufacturing technology are presented as the enabling mechanisms for increased domestic biologics production and affordability, framed within national objectives of equitable healthcare access. News - Thu, 25 Sep 2025 14:46:02 +0530 https://www.taxtmi.com/news?id=56892